Workflow
饲料添加剂
icon
Search documents
农业农村部批了 花园生物胆固醇成新饲料添加剂
1月12日晚,花园生物(300401)公告称,根据《新饲料和新饲料添加剂管理办法》等相关规定,经农 业农村部审查,批准花园生物及其全资子公司浙江花园营养科技有限公司联合申报的"胆固醇(源自'羊 毛脂')"为新饲料添加剂,农业农村部于2026年1月12日核发了《新饲料添加剂证书》。 根据公告,胆固醇以羊毛脂为原料,经皂化、提取、结晶、干燥等工艺制得,适用于虾。用量方面,在 配合饲料中的推荐添加量(以干物质含量为88%的配合饲料为基础)为1.0—2.0g/kg;在配合饲料中的最高 限量(以干物质含量为88%的配合饲料为基础)为10g/kg(在仔虾阶段为20g/kg)。 胆固醇(源自"羊毛脂")作为新饲料(适用于"虾")添加剂,市场容量有多大?据中国饲料工业协会数据, 2024年全国工业饲料总产量达31503.1万吨,其中,水产饲料产量约2262万吨,占全国饲料总产量的 7.18%。虾饲料具体产量不详,但虾饲料是水产饲料的重要组成部分。 用途方面,纯度95%以上的羊毛脂胆固醇(NF级胆固醇)是生产维生素D3的主要原材料,低含量的胆固醇 用于虾饲料,胆固醇还可用于医药领域生产胆甾醇酯、甾类激素,化妆品领域中乳液、面霜 ...
研判2025!中国饲料级维生素E行业产业链、相关政策、产量及发展趋势分析:受终端养殖规模缩减影响,饲料级维生素E产量同比下降3.2%[图]
Chan Ye Xin Xi Wang· 2025-07-02 01:12
Core Viewpoint - The production of feed-grade vitamin E in China has shown a fluctuating upward trend, with a notable decline in 2022 due to losses in the terminal breeding industry, but a gradual recovery is expected in subsequent years [1][12]. Group 1: Industry Overview - Feed-grade vitamin E is a fat-soluble vitamin essential for animal feed, known for its antioxidant properties, which enhance meat quality, growth, and survival rates [3][12]. - The production of feed-grade vitamin E primarily relies on synthetic methods due to higher efficiency and lower costs [3][12]. Group 2: Production Trends - In 2022, China's production of feed-grade vitamin E decreased by 8.3% year-on-year, primarily due to strong cost control measures in the breeding industry [1][12]. - By 2024, the production is projected to reach 63,000 tons, reflecting a year-on-year decline of 3.2% [1][12]. Group 3: Policy Support - Various policies have been introduced to promote the development of feed-grade vitamin E, including its inclusion in the encouraged foreign investment industry directory [5][7]. - The 2025 regulatory framework includes vitamin premix feed in the supervision and inspection projects, indicating a focus on quality and safety [5][7]. Group 4: Competitive Landscape - The market features a mix of international brands like DSM and domestic companies such as Zhejiang Medicine and Xinhecheng, with the latter gaining market share through innovation [14][15]. - Emerging brands are also making their mark through differentiated competition and targeted marketing strategies [14]. Group 5: Future Trends - The demand for feed-grade vitamin E is expected to rise with the ongoing development of the global livestock industry and increased awareness of animal health [19]. - Technological innovations and sustainable production methods will drive the industry's future growth, with a focus on environmental considerations [19].
圣达生物: 浙江圣达生物药业股份有限公司向特定对象发行股票证券募集说明书(注册稿)
Zheng Quan Zhi Xing· 2025-05-22 10:28
Group 1 - The company Zhejiang Shengda Bio-Pharm Co., Ltd. plans to issue shares to specific investors, with the total amount of funds raised not exceeding 267.61 million yuan [1][2] - The issuance has been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The funds raised will be used for a project to produce 20,000 tons of D-isomeric ascorbic acid and its sodium salt, with a total investment of 368 million yuan [1][2] Group 2 - The issuance will involve no more than 51,356,687 shares, which is capped at 30% of the company's total share capital prior to the issuance [2][3] - The final number of shares to be issued will be determined based on the actual situation at the time of issuance [3] - Shares acquired through this issuance will be subject to a six-month lock-up period [3][4] Group 3 - The company has a plan for shareholder returns over the next three years (2023-2025), considering factors such as operational development and shareholder expectations [4] - The company will adjust the order and amount of funds allocated to projects if the actual funds raised are less than the planned investment [2][4] - The company has committed to measures to mitigate the impact of immediate return dilution on small investors [4][5] Group 4 - The company operates in the food and feed additive industry, focusing on products such as biotin and lactic acid bacteriocin [5][6] - The industry is experiencing rapid growth, but increased competition may affect profit margins [5][6] - The company has established a significant position in the market, being one of the earliest developers of biotin and biological preservatives in China [5][6]